Merck Opens Climate-Neutral €150 Million Manufacturing Facility in Ireland
The Blarney Business Park facility is part of Merck’s largest Life Science investment to date
Advertisement
Merck has opened its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040.
The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers.
“Ireland is a leading hub for biopharmaceutical manufacturing and innovation for Europe and globally. By expanding manufacturing in Cork, we reinforce our in-region-for-region manufacturing and supply model, reducing cross-border risks and providing manufacturers with reliable access to critical filtration technologies they need to deliver life-changing therapies”, said Jean-Charles Wirth, Member of the Executive Board of Merck and CEO Life Science.
The facility is expected to begin production in the fourth quarter of 2025 and will manufacture filtration devices used in aseptic processing, tangential-flow filtration and virus filtration. These filtration technologies are key components of most bioprocessing templates and are vital to controlling bioburden, streamlining purification and removing viral contaminants. They assure vaccines and therapeutics meet expected purity standards and are safe for administration to patients.
The new site will run on 100% renewable electricity and an innovative heat recovery system, which is estimated to avoid up to 61 metric tons of CO2 equivalents annually. It will also reuse up to 95% of high-purity reverse osmosis water from its filtration manufacturing process.
The Blarney Business Park facility is part of Merck’s largest Life Science investment to date. Together with the nearby Carrigtwohill site, the company has committed €440 million to expand membrane and filtration manufacturing in Ireland. These investments are part of Merck’s €2 billion Life Science global expansion program, announced in 2020, to meet growing demand for life-saving therapies across Europe, China, and the United States.
Other news from the department manufacturing
These products might interest you
Most read news
More news from our other portals
Last viewed contents
Simtra BioPharma Solutions expands U.S. manufacturing capacity for injectable medicines - Simtra positioned to become the first CDMO to offer commercial-scale drug product manufacturing of antibody-drug conjugates in the United States
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ChatGPT grows insect-toxic genetically engineered plant - Blind spot in the EU draft law on genetic engineering
Commission launches new strategy to make Europe a global leader in life sciences by 2030
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech - BioNTech’s acquisition of CureVac will be implemented as planned
Ibidi Awarded With the German bAV Prize 2023
Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively
EXIST start-up grant for virtual reality laboratory training - "Wet-Lab-VR": Virtual reality technology revolutionises training for molecular biology laboratories
Sustainable Plastics from Plants - Innovative interdisciplinary education model
How immune cells become accomplices of tumors - Langener Wissenschaftspreis awarded to DKFZ researcher Daniel Kirschenbaum
How the biological clock ticks in the female reproductive tract - Breakthrough of the Year Award 2025 for Ângela Gonçalves
